Isoniazid News and Research

RSS

Real-world management and outcomes of U.S. patients treated with BpaL for rifampin-resistant tuberculosis

Researchers reported on the treatment of rifampin-resistant tuberculosis in the United States using the FDA approved bedaquiline, pretomanid, and linezolid (BPaL) therapy.

1 Jun 2023

Revolution in MDR-TB treatment: Shorter all-oral regimens

Researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy.

6 Apr 2023

The rapid diagnosis of drug-resistant and drug-sensitive tuberculosis using mass spectrometry and machine learning

In a recent study posted to the Preprints with The Lancet SSRN* server, a team of researchers in China developed a machine learning-based diagnostic tool to detect tuberculosis and drug-resistant tuberculosis using nanoparticle-enhanced laser desorption/ionization mass spectrometry (NPELDI MS) to determine metabolic fingerprints from serum samples.

28 Feb 2023

Study identifies a protein in Mycobacterium tuberculosis that contributes to drug tolerance

Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.

4 May 2022

Study explores decline in tuberculosis cases during COVID-19 pandemic in the United States

Researchers analyzed a pharmacy dataset to evaluate the 20% decrease in tuberculosis cases reported in 2020 by the US National Tuberculosis Surveillance System.

21 Mar 2022

ACTG announces launch of clinical trial evaluating a three-month TB treatment

The AIDS Clinical Trials Group (ACTG), the largest global HIV research network, today announced the launch of A5362 (CLO-FAST), a clinical trial studying a three-month clofazimine- and high-dose rifapentine-containing treatment regimen for people with drug-susceptible tuberculosis (TB).

10 Nov 2021

Weill Cornell receives NIH support to advance TB research

Tuberculosis (TB) is one of the deadliest infectious diseases in history and one of the few that naturally infects only humans.

4 Sep 2021

Study: Four-month regimen of anti-TB drugs works just as well as standard regimen

A new four-month regimen of anti-TB drugs that includes rifapentine and moxifloxacin works just as well as the standard six-month regimen, according to a study.

24 May 2021

Four months of multi-drug therapy for tuberculosis is as effective as standard regimen

Four months of multi-drug therapy that included rifapentine and moxifloxacin treated active tuberculosis (TB) as effectively as the standard six-month regimen in a multinational study, cutting treatment time by a third.

20 May 2021

Designing effective multidrug-resistant-TB treatments based on DNA sequencing

Globally, tuberculosis is the most common bacterial infectious disease leading to death. The pathogen causing tuberculosis, Mycobacterium tuberculosis, has a number of peculiarities. One is that it is growing very slowly.

3 May 2021

New drug cocktail offers hope to patients with highly drug-resistant tuberculosis

A new three-drug, all-oral, six-month treatment is providing hope to patients in Tajikistan with highly drug-resistant forms of tuberculosis, which until now had limited treatment options and poor prognosis.

3 Feb 2021

WHO revises definition of extensively drug-resistant tuberculosis

The definition of extensively drug-resistant tuberculosis (XDR-TB) has been revised by the World Health Organization's Global TB Programme, who have also defined pre-XDR-TB for the first time, highlighting the seriousness of these forms of TB.

1 Feb 2021

Overcoming pediatric drug-resistant TB crisis

World Children's Day marks the day, over three decades ago, on which world leaders adopted the historic Convention of the Rights of the Child, promising to every child to promote and protect their rights, including the right to life and the right to health.

30 Nov 2020

TB screening needed for people on methotrexate who live in at-risk areas

New research presented at ACR Convergence, the American College of Rheumatology's annual meeting, shows that tuberculosis (TB) screening and ongoing clinical care is needed for people on methotrexate who live in areas where the highly infectious illness is common.

6 Nov 2020

WHO welcomes SHINE trial results on shorter treatment for drug-susceptible TB in children

The World Health Organization's Global TB Programme welcomes the results from an important study on shortened treatment for drug-susceptible tuberculosis in children, presented at the 51st virtual Union World Conference on Lung Health.

2 Nov 2020

NTU-incubated start-up plans clinical trial of new slow-release pill for Parkinson’s disease

Materials scientists from Nanyang Technological University, Singapore (NTU Singapore) have developed a new pill which uses the stomach as a drug reservoir and delivers medicines slowly over time to patients with Parkinson's disease (PD).

16 Sep 2020

New recommendations to tackle tuberculosis amid coronavirus crisis

The World Health Organization has today issued new recommendations to tackle tuberculosis, a respiratory disease, in the wake of coronavirus spreading across continents.

25 Mar 2020

Combination of two antibiotics eradicates latent tuberculosis in macaques

A major goal of tuberculosis (TB) research is to find a way to treat people with the latent (or inactive) form of the disease to keep them from developing symptomatic TB.

17 Dec 2019

New clinical guideline for treatment of drug-resistant tuberculosis published

The American Thoracic Society, Centers for Disease Control and Prevention, European Respiratory Society and the Infectious Diseases Society of America have published an official clinical guideline on the treatment of drug-resistant tuberculosis in the Nov. 15 American Journal of Respiratory and Critical Care Medicine.

18 Nov 2019

New sensor technology to revolutionize treatment and cure of tuberculosis

A trial involving an edible sensor connected to a paired mobile, that enables medical staff to remotely see patients` intake of tuberculosis (TB) medicine, has produced superior results to directly observed therapy (DOT), where a healthcare worker watches the patient swallow medication, leading researchers to suggest that the technology could be a game changer in high prevalence countries where treatment adherence remains a stumbling block to eliminating TB.

4 Oct 2019